Form 4 for NAMS NewAmsterdam Pharma Co N.V.
Accepted 2024-03-28 00:00:00 ET · period of report 2024-03-26 · accession 0001415889-24-009330 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-03-28 | 2024-03-26 | NAMS | Topper James N | Dir | P - Purchase | $21.50 | +8,429 | 3.01M | +0.3% | +$181.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2024-03-26 | P | A | 8,429 | $21.50 | 3,008,429 | I By Frazier Life Sciences X, L.P. | — | — | (F1) The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |